Aliases & Classifications for Bronchiectasis

MalaCards integrated aliases for Bronchiectasis:

Name: Bronchiectasis 12 76 29 55 44 15 63 73
Polynesian Bronchiectasis 12
Kartagener Syndrome 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9563
ICD10 33 J47 J47.9
ICD9CM 35 494
MeSH 44 D001987
NCIt 50 C84475
SNOMED-CT 68 12295008

Summaries for Bronchiectasis

PubMed Health : 63 About bronchiectasis: Bronchiectasis (brong-ke-EK-tah-sis) is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of your lungs.Bronchiectasis often is caused by an infection or other condition that injures the walls of the airways or prevents the airways from clearing mucus. Mucus is a slimy substance. It helps remove inhaled dust, bacteria, and other small particles from the airways.In bronchiectasis, your airways slowly lose their ability to clear out mucus. The mucus builds up, and bacteria begin to grow. This leads to repeated, serious lung infections.Each infection causes more damage to the airways. Over time, the airways can't properly move air in and out of the lungs. As a result, the body's vital organs might not get enough oxygen.Bronchiectasis can lead to serious health problems, such as respiratory failure, atelectasis (at-eh-LEK-tah-sis), and heart failure.

MalaCards based summary : Bronchiectasis, also known as polynesian bronchiectasis, is related to bronchiectasis with or without elevated sweat chloride 1 and idiopathic bronchiectasis, and has symptoms including headache An important gene associated with Bronchiectasis is CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), and among its related pathways/superpathways are Innate Immune System and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Tobramycin and Amikacin have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are immune system and mortality/aging

Disease Ontology : 12 A bronchial disease that is a chronic inflammatory condition of one or more bronchi or bronchioles marked by dilatation and loss of elasticity of the walls resulting from damage to the airway wall leading to the formation of small sacs on the bronchial wall and impairment of cilia mobility in the lung. Inflammation of the bronchial wall increases mucus secretion which serves as a breeding ground for bacteria. Bronchiectasis is caused by repeated respiratory infections, immune deficiency disorders, hereditary disorders (cystic fibrosis or primary ciliary dyskinesia), mechanical factors (inhaled object or a lung tumor) or inhaling toxic substances.

Wikipedia : 76 Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung.... more...

Related Diseases for Bronchiectasis

Diseases related to Bronchiectasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)
# Related Disease Score Top Affiliating Genes
1 bronchiectasis with or without elevated sweat chloride 1 34.0 CFTR SCNN1B
2 idiopathic bronchiectasis 33.7 CFTR SCNN1A SCNN1B SCNN1G
3 ciliary dyskinesia, primary, 1 33.0 CCDC40 DNAH5 DNAI1
4 kartagener syndrome 32.9 CCDC40 DNAH5 DNAI1
5 nontuberculous mycobacterial lung disease 31.7 CFTR TLR2
6 cystic fibrosis 30.8 BPI CFTR CTSG CXCL8 ELANE MBL2
7 situs inversus 30.3 CCDC40 DNAH5 DNAI1
8 bronchitis 30.3 CFTR CXCL8 ELANE MPO SERPINA1
9 respiratory failure 30.1 CXCL8 ELANE SERPINA1
10 haemophilus influenzae 30.0 CXCL8 TLR2
11 alpha-1-antitrypsin deficiency 30.0 BPI CXCL8 ELANE SERPINA1 SERPINA3
12 aspergillosis 30.0 CFTR ELANE MBL2 TLR2
13 pulmonary emphysema 29.9 ELANE MMP8 SERPINA1
14 mycobacterium abscessus 29.8 CFTR CXCL8 SERPINA1 TLR2
15 pneumonia 29.8 CXCL8 ELANE MBL2 MPO TLR2
16 anca-associated vasculitis 29.8 MPO SERPINA1
17 pulmonary disease, chronic obstructive 29.7 CFTR CXCL8 ELANE MPO SERPINA1 SERPINA3
18 ulcerative colitis 29.7 BPI CXCL8 MPO
19 crescentic glomerulonephritis 29.7 BPI CTSG MPO
20 bronchopneumonia 29.6 ELANE MPO
21 vasculitis 29.5 BPI CTSG ELANE MPO SERPINA1
22 sclerosing cholangitis 29.3 BPI CFTR CTSG MPO
23 lung disease 29.3 CFTR CTSG CXCL8 ELANE MBL2 MMP8
24 bronchiectasis with or without elevated sweat chloride 2 12.4
25 bronchiectasis with or without elevated sweat chloride 3 12.4
26 ciliary dyskinesia-bronchiectasis 12.1
27 bronchiectasis oligospermia 12.0
28 primary ciliary dyskinesia 11.4
29 yellow nail syndrome 11.3
30 panbronchiolitis, diffuse 11.3
31 mounier-kuhn syndrome 11.2
32 bare lymphocyte syndrome, type i 11.2
33 tracheobronchomegaly 11.2
34 ciliary dyskinesia, primary, 25 11.1
35 ciliary dyskinesia, primary, 26 11.1
36 ciliary dyskinesia, primary, 27 11.1
37 ciliary dyskinesia, primary, 28 11.1
38 ciliary dyskinesia, primary, 32 11.1
39 cutis laxa, autosomal dominant 1 11.0
40 young syndrome 11.0
41 ciliary dyskinesia, primary, 9 11.0
42 ciliary dyskinesia, primary, 11 11.0
43 ciliary dyskinesia, primary, 12 11.0
44 ciliary dyskinesia, primary, 22 11.0
45 ciliary dyskinesia, primary, 23 11.0
46 ciliary dyskinesia, primary, 30 11.0
47 ciliary dyskinesia, primary, 36, x-linked 10.8
48 ciliary dyskinesia, primary, 2 10.8
49 ciliary dyskinesia, primary, 3 10.8
50 ciliary dyskinesia, primary, 5 10.8

Comorbidity relations with Bronchiectasis via Phenotypic Disease Network (PDN): (show all 20)


Agammaglobulinemia, X-Linked Anxiety
Aspergillosis Bronchitis
Bronchopneumonia Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Idiopathic Interstitial Pneumonia
Lung Abscess Mitral Valve Disease
Osteoporosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Pulmonary Tuberculosis
Respiratory Failure Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Bronchiectasis:



Diseases related to Bronchiectasis

Symptoms & Phenotypes for Bronchiectasis

UMLS symptoms related to Bronchiectasis:


headache

MGI Mouse Phenotypes related to Bronchiectasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.91 CFTR CTSG DNAH5 DNAI1 ELANE MBL2
2 mortality/aging MP:0010768 9.9 CCDC40 CFTR CTSG DNAH5 DNAI1 ELANE
3 renal/urinary system MP:0005367 9.5 CCDC40 DNAH5 MBL2 SCNN1A SCNN1B SCNN1G
4 respiratory system MP:0005388 9.23 CCDC40 CFTR DNAH5 DNAI1 SCNN1A SCNN1B

Drugs & Therapeutics for Bronchiectasis

PubMedHealth treatment related to Bronchiectasis: 63

Bronchiectasis often is treated with medicines, hydration, and chest physical therapy (CPT). Your doctor may recommend surgery if the bronchiectasis is isolated to a section of lung or you have a lot of bleeding.If the bronchiectasis is widespread and causing respiratory failure, your doctor may recommend oxygen therapy.The goals of treatment are to:Treat any underlying conditions and lung infections.Remove mucus (a slimy substance) from your lungs. Maintaining good hydration helps with mucus removal.Prevent complications.Early diagnosis and treatment of the underlying cause of bronchiectasis may help prevent further lung damage. In addition, any disease associated with the bronchiectasis, such as cystic fibrosis or immunodeficiency, also should be treated.

Drugs for Bronchiectasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 32986-56-4 36294 5496
2
Amikacin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 37517-28-5 37768
3
Budesonide Approved Phase 4,Not Applicable 51333-22-3 63006 5281004
4
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Not Applicable 616-91-1 12035
5
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
6
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
7
Fluticasone Approved, Experimental Phase 4,Phase 2 90566-53-3 62924
8
Theophylline Approved Phase 4 58-55-9 2153
9
Ivacaftor Approved Phase 4,Phase 2 873054-44-5 16220172
10
Meropenem Approved, Investigational Phase 4 119478-56-7 64778 441130
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
13
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
14 Andrographolide Investigational Phase 4 5508-58-7
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Ergocalciferols Phase 4
18 Vitamin D2 Phase 4
19 Vitamins Phase 4
20 Calciferol Phase 4
21 Trace Elements Phase 4
22 Micronutrients Phase 4
23 Bone Density Conservation Agents Phase 4,Not Applicable
24 Anti-Asthmatic Agents Phase 4,Phase 2,Not Applicable
25 Neurotransmitter Agents Phase 4,Not Applicable
26 Parasympatholytics Phase 4
27 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable
28 Bronchodilator Agents Phase 4,Phase 2,Not Applicable
29 Cholinergic Antagonists Phase 4
30 Formoterol Fumarate Phase 4,Not Applicable
31 Respiratory System Agents Phase 4,Phase 2,Not Applicable
32 Tiotropium Bromide Phase 4 136310-93-5
33 Cholinergic Agents Phase 4
34 Anticonvulsants Phase 4
35 Budesonide, Formoterol Fumarate Drug Combination Phase 4,Not Applicable
36 Bromides Phase 4
37 Autonomic Agents Phase 4,Phase 2,Not Applicable
38 Antiviral Agents Phase 4
39 Expectorants Phase 4,Phase 2,Not Applicable
40 Antidotes Phase 4,Phase 1
41 Free Radical Scavengers Phase 4,Not Applicable
42 Protective Agents Phase 4,Phase 1,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
44 N-monoacetylcystine Phase 4,Phase 3,Not Applicable
45 Antioxidants Phase 4,Not Applicable
46 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3
47 Immunologic Factors Phase 4,Phase 3
48 Immunoglobulins Phase 4,Phase 3
49 Vaccines Phase 4,Phase 3
50 Antibodies Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 287)
# Name Status NCT ID Phase Drugs
1 A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis Unknown status NCT01677403 Phase 4 Tobramycin;Saline
2 Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis Unknown status NCT02507843 Phase 4 Cholecalciferol;Placebo
3 Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Unknown status NCT02081963 Phase 4 Amikacin;Normal saline
4 Comparisons of Inhaled LAMA or ICS+LABA for COPD With Bronchiectasis Unknown status NCT02546297 Phase 4 Symbicort;Tiotropium Bromide
5 Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis Unknown status NCT02088216 Phase 4 N-acetylcysteine;Placebo
6 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
7 Polysaccharide Antibody Response Study Unknown status NCT02429531 Phase 4
8 Prevention of OM-85 on Bronchiectasis Exacerbation Completed NCT01968421 Phase 4 OM-85
9 Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis Completed NCT02782312 Phase 4 ICS+LABA
10 The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Completed NCT01769898 Phase 4 Formoterol-budesonide;Theophylline;Placebo
11 Efficacy of Azithromycin in Treatment of Bronchiectasis Completed NCT02107274 Phase 4 Azithromycin;Placebo for Azithromycin
12 Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Completed NCT00816309 Phase 4
13 The Effect of Theophylline in the Treatment of Bronchiectasis Completed NCT01684683 Phase 4 Theophylline;Placebo(for Theophylline)
14 Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa Completed NCT01299194 Phase 4 ATORVASTATIN
15 A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Completed NCT01299181 Phase 4 Atorvastatin
16 Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Completed NCT00868075 Phase 4
17 Long Term Nebulised Gentamicin in Patients With Bronchiectasis Completed NCT00749866 Phase 4 Gentamicin;Saline
18 Effectiveness and Safety of Inhaling Hypertonic Saline in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00639236 Phase 4
19 Efficacy of Temporary Positive Expiratory Pressure (TPEP) in Chronic Hypersecretion Completed NCT00700388 Phase 4
20 Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation Completed NCT01109160 Phase 4 Azithromycin Dihydrate
21 Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations Recruiting NCT02047773 Phase 4 Colomycin;Meropenem
22 Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis Recruiting NCT02509091 Phase 4 Bronchoalveolar Lavage and Local Amikacin Injection
23 Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials Recruiting NCT03147443 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
24 Hospitalised Pneumonia With Extended Treatment (HOPE) Study Recruiting NCT02783859 Phase 4 Amoxicillin-clavulanic Acid;Placebo (for Amoxicillin-clavulanic Acid)
25 Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis Recruiting NCT03132623 Phase 4 andrographolide sulfonate;andrographolide sulfonate simulation
26 Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis Not yet recruiting NCT03737617 Phase 4 Cuvitru 20 % Injectable Solution
27 VX-770 for the Treatment of Chronic Bronchitis Not yet recruiting NCT03251911 Phase 4 Ivacaftor (VX-770)
28 "Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use: A Randomized Controlled Trial" Inpatient Hospital Use: A Randomized Controlled Trial" Not yet recruiting NCT03364218 Phase 4 N acetyl cysteine nebulized
29 Bronchiectasis and Long Term Azithromycin Treatment Unknown status NCT00415350 Phase 3 Azithromycin
30 The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis Unknown status NCT02531984 Phase 3 Azithromycin
31 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
32 An Open Label Trial of Azithromycin in Chronic Productive Cough Unknown status NCT02196493 Phase 3 Azithromycin
33 Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed NCT02106832 Phase 3 Ciprofloxacin (BAYQ3939) dry powder for inhalation;Ciprofloxacin (BAYQ3939) dry powder for inhalation;Placebo;Placebo
34 Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed NCT01764841 Phase 3 Ciprofloxacin DPI (BAYQ3939);Placebo
35 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4) Completed NCT02104245 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
36 Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3) Completed NCT01515007 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
37 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed NCT01313624 Phase 3 AZLI;Placebo
38 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed NCT01314716 Phase 3 AZLI;Placebo
39 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis Completed NCT00669331 Phase 3 Inhaled mannitol;Matched control
40 The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis Completed NCT00484263 Phase 3 Hypertonic saline 6% -
41 Safety and Efficacy of Bronchitol in Bronchiectasis Completed NCT00277537 Phase 3 Mannitol;placebo
42 Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage Completed NCT01480882 Phase 2, Phase 3
43 Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization Completed NCT01973998 Phase 3 Roflumilast;Placebo
44 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
45 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed NCT00105183 Phase 3
46 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher Completed NCT00380315 Phase 3 AG1321001(drug)
47 Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF Completed NCT01641822 Phase 3 AZLI;Placebo to match AZLI;Tobramycin inhalation solution
48 Prevention of Bronchiectasis in Infants With Cystic Fibrosis Recruiting NCT01270074 Phase 3 Azithromycin;Placebo control
49 Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis Recruiting NCT02657473 Phase 2, Phase 3 tobramycin inhalation solution;Saline 0.9% inhalation solution
50 Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS-2) Recruiting NCT03460704 Phase 3 Colistimethate sodium;Saline Solution

Search NIH Clinical Center for Bronchiectasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: bronchiectasis

Genetic Tests for Bronchiectasis

Genetic tests related to Bronchiectasis:

# Genetic test Affiliating Genes
1 Bronchiectasis 29

Anatomical Context for Bronchiectasis

MalaCards organs/tissues related to Bronchiectasis:

41
Lung, Testes, Heart, Neutrophil, Colon, Liver, Kidney

Publications for Bronchiectasis

Articles related to Bronchiectasis:

(show top 50) (show all 1423)
# Title Authors Year
1
Bronchiectasis and asthma: a dangerous liaison? ( 30516546 )
2019
2
Bronchiectasis in severe asthma: a distinct phenotype? ( 30461531 )
2019
3
Updated BTS Adult Bronchiectasis Guideline 2018: a multidisciplinary approach to comprehensive care. ( 30545946 )
2019
4
British Thoracic Society Guideline for bronchiectasis in adults. ( 30545985 )
2019
5
Bronchiectasis Revisited: Imaging-Based Pattern Approach to Diagnosis. ( 29530453 )
2019
6
Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison. ( 30101613 )
2019
7
Development of a core outcome set for trials investigating the long-term management of bronchiectasis. ( 30278785 )
2019
8
<i>Pseudomonas aeruginosa</i> infection and exacerbations in bronchiectasis: more questions than answers. ( 29386340 )
2018
9
Effects of exercise on secretion transport, inflammation, and quality of life in patients with noncystic fibrosis bronchiectasis: Protocol for a randomized controlled trial. ( 29443739 )
2018
10
Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease. ( 29848315 )
2018
11
Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis. ( 29435737 )
2018
12
Continuous versus intermittent antibiotics for bronchiectasis. ( 29860722 )
2018
13
Dual antibiotics for bronchiectasis. ( 29889304 )
2018
14
Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis. ( 29806511 )
2018
15
Bronchiectasis and Multidrug-resistant Microorganisms: The Ideal Niche? ( 29929708 )
2018
16
RESPIRE: breathing new life into bronchiectasis. ( 29371393 )
2018
17
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( 29371383 )
2018
18
Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. ( 29915333 )
2018
19
Subclinical atherosclerosis in adults with steady-state bronchiectasis: A case-control study. ( 29413496 )
2018
20
Bronchial wash culture is less valuable in patients suspected to have nontuberculous mycobacteria lung disease for bilateral bronchiectasis with nodules. ( 29900897 )
2018
21
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( 29371384 )
2018
22
Noninvasive Ventilation for Acute Respiratory Failure due to Noncystic Fibrosis Bronchiectasis. ( 29910541 )
2018
23
Association between I+<sub>1</sub>-antitrypsin and bronchiectasis in patients with humoral immunodeficiency receiving gammaglobulin infusions. ( 29413345 )
2018
24
Hip Fracture and Palpitations in a 92-Year-Old Woman With Bronchiectasis. ( 29450461 )
2018
25
Epidemiology and natural history of <i>Pseudomonas aeruginosa</i> airway infections in non-cystic fibrosis bronchiectasis. ( 29930949 )
2018
26
Antibiotic-resistant<i>Pseudomonas aeruginosa</i>infection in patients with bronchiectasis: prevalence, risk factors and prognostic implications. ( 29386892 )
2018
27
Acute respiratory events in patients with bronchiectasis-COPD overlap syndrome: A population-based cohort study. ( 29957282 )
2018
28
Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. ( 29878856 )
2018
29
The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation. A case-crossover analysis. ( 29903857 )
2018
30
Pulmonary Rehabilitation Only Versus With Nutritional Supplementation in Patients With Bronchiectasis: A RANDOMIZED CONTROLLED TRIAL. ( 29952809 )
2018
31
Nontuberculous mycobacterial lung disease in a patient with COPD and bronchiectasis, with radiological signs of lung tumor. ( 29490418 )
2018
32
IMMUNOLOGICAL COROLLARY OF THE PULMONARY MYCOBIOME IN BRONCHIECTASIS: THE CAMEB STUDY. ( 29880655 )
2018
33
Upper airway involvement in bronchiectasis is marked by early onset and allergic features. ( 29362708 )
2018
34
Self-management for bronchiectasis. ( 29411860 )
2018
35
Nurse-led versus doctor-led care for bronchiectasis. ( 29926473 )
2018
36
Atorvastatin in Bronchiectasis With Chronic Pseudomonas Infection. ( 29406230 )
2018
37
Pulmonary hemangioma mimicking bronchiectasis: A case report. ( 29924044 )
2018
38
Adult Cystic Fibrosis: A Possible Cause of Bronchiectasis in COPD Patients. ( 29935777 )
2018
39
Inhaled medication therapy for bronchiectasis: status quo and the next frontier. ( 29425474 )
2018
40
Bronchiectasis: Phenotyping an Orphan Disease. ( 29412693 )
2018
41
A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart. ( 29886096 )
2018
42
Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. ( 29416328 )
2018
43
Aspergillus fumigatus Detection and Risk Factors in Patients with COPD-Bronchiectasis Overlap. ( 29425123 )
2018
44
Gender differences in bronchiectasis: a real issue? ( 29875830 )
2018
45
The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: a multi-centre, double-blind, randomised controlled trial. ( 29944440 )
2018
46
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. ( 29588830 )
2018
47
Physical activity associates with disease characteristics of severe asthma, bronchiectasis and COPD. ( 30384396 )
2018
48
Bronchiectasis and Chronic Airway Disease: It Is Not Just About Asthma and COPD. ( 30290922 )
2018
49
Bronchiectasis in COPD and Asthma. More Than Just a Coincidence. ( 30314689 )
2018
50
Validation of the Incremental Shuttle Walk Test as a Clinical End Point in Bronchiectasis. ( 30300653 )
2018

Variations for Bronchiectasis

Expression for Bronchiectasis

Search GEO for disease gene expression data for Bronchiectasis.

Pathways for Bronchiectasis

GO Terms for Bronchiectasis

Cellular components related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 BPI CTSG ELANE MPO SCNN1A SCNN1B
2 cell surface GO:0009986 9.85 CFTR CTSG ELANE MBL2 TLR2
3 cilium GO:0005929 9.81 CCDC40 DNAH5 DNAI1 SCNN1A
4 extracellular space GO:0005615 9.81 BPI CTSG CXCL8 ELANE MBL2 MMP8
5 apical plasma membrane GO:0016324 9.8 CFTR SCNN1A SCNN1B SCNN1G
6 secretory granule GO:0030141 9.65 CTSG ELANE MPO
7 collagen-containing extracellular matrix GO:0062023 9.65 CTSG ELANE MMP8 SERPINA1 SERPINA3
8 specific granule lumen GO:0035580 9.58 BPI ELANE MMP8
9 outer dynein arm GO:0036157 9.43 DNAH5 DNAI1
10 sodium channel complex GO:0034706 9.13 SCNN1A SCNN1B SCNN1G
11 azurophil granule lumen GO:0035578 9.02 BPI CTSG ELANE MPO SERPINA3
12 extracellular region GO:0005576 10.02 BPI CTSG CXCL8 ELANE MBL2 MMP8

Biological processes related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.8 CTSG ELANE MPO TLR2
2 sodium ion transport GO:0006814 9.77 SCNN1A SCNN1B SCNN1G
3 neutrophil degranulation GO:0043312 9.76 BPI CTSG ELANE MMP8 MPO SERPINA1
4 defense response to Gram-positive bacterium GO:0050830 9.75 CTSG MBL2 TLR2
5 sodium ion transmembrane transport GO:0035725 9.72 SCNN1A SCNN1B SCNN1G
6 defense response to bacterium GO:0042742 9.72 BPI CTSG ELANE MBL2 MPO
7 flagellated sperm motility GO:0030317 9.71 CCDC40 DNAH5 DNAI1
8 extracellular matrix disassembly GO:0022617 9.7 CTSG ELANE MMP8
9 antimicrobial humoral response GO:0019730 9.69 BPI CTSG ELANE
10 sensory perception of taste GO:0050909 9.63 SCNN1A SCNN1B SCNN1G
11 acute-phase response GO:0006953 9.61 MBL2 SERPINA1 SERPINA3
12 outer dynein arm assembly GO:0036158 9.59 DNAH5 DNAI1
13 epithelial cilium movement GO:0003351 9.58 CCDC40 DNAI1
14 cilium movement GO:0003341 9.58 CCDC40 DNAH5 DNAI1
15 response to molecule of bacterial origin GO:0002237 9.57 CXCL8 TLR2
16 positive regulation of immune response GO:0050778 9.56 CTSG ELANE
17 defense response to fungus GO:0050832 9.54 CTSG ELANE MPO
18 response to yeast GO:0001878 9.48 ELANE MPO
19 sodium ion homeostasis GO:0055078 9.43 SCNN1A SCNN1B SCNN1G
20 negative regulation of growth of symbiont in host GO:0044130 9.26 CTSG ELANE MBL2 MPO
21 multicellular organismal water homeostasis GO:0050891 8.92 CFTR SCNN1A SCNN1B SCNN1G

Molecular functions related to Bronchiectasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.46 CTSG ELANE MBL2 MMP8
2 dynein light chain binding GO:0045503 9.26 DNAH5 DNAI1
3 WW domain binding GO:0050699 9.13 SCNN1A SCNN1B SCNN1G
4 ligand-gated sodium channel activity GO:0015280 8.8 SCNN1A SCNN1B SCNN1G

Sources for Bronchiectasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....